Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | See "Remarks" | May 01, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 80,760 |
Reported balance
After 2026-05-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-01 · Sale · Disposed 144,180 · Balance 80,760 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 4, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 144,180 | $34.99 | $5,045,117.72 |
DisclosureSEC source: 0001193125-26-203928 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,760 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 62,102 | $30.14 | $1,871,816.38 |
DisclosureSEC source: 0001193125-26-115929 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,940 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.115 to $30.215, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098582 · ownership.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,170 Underlying: Ordinary Shares · 15,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098582 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 30,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,385 Underlying: Ordinary Shares · 30,385 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 7,596 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 7,597 vesting on March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 18,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,202 Underlying: Ordinary Shares · 18,601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on each of March 4, 2025 and March 4, 2026, and 18,601 vesting on each of March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096538 · ownership.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 18,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096538 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096538 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 141,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093938 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 141,478 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F4 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093938 · ownership.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,901 Underlying: Ordinary Shares · 24,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2024, with 24,900 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 141,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093938 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093938 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 141,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029312 · ownership.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,478 Underlying: Ordinary Shares · 141,478 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionStock Options (right to buy) · Derivative | 118,724 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001193125-25-315923 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 118,724 shares Expires 2028-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 98,168 | $28.70 | $2,817,676.84 |
DisclosureSEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,828 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 118,724 | $28.75 | $3,413,077.55 |
DisclosureSEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,996 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 118,724 | $18.61 | $2,209,453.64 |
DisclosureSEC source: 0001193125-25-315923 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 337,915 | $18.04 | $6,097,304.47 |
DisclosureSEC source: 0000950170-25-069132 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,996 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.865 to $18.265, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 62,893 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035512 · ownership.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,893 Underlying: Ordinary Shares · 62,893 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 15,723 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035512 · ownership.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,765 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025. F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vested on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-035512 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 183,169 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 6 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 183,169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025. F5 · derivative.expiration_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 18,601 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,803 Underlying: Ordinary Shares · 18,601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,512 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 183,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 18,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034617 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033597 · ownership.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,801 Underlying: Ordinary Shares · 24,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-033597 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 177,626 | $16.25 | $2,886,564.60 |
DisclosureSEC source: 0000950170-25-021151 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,964 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.335, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 183,169 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011064 · ownership.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,169 Underlying: Ordinary Shares · 183,169 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 58,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027959 · ownership.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 58,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. F5 · derivative.expiration_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,764 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027959 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,765 Underlying: Ordinary Shares · 23,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025. F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022, March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 100,000 | $13.52 | $1,352,090.00 |
DisclosureSEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,590 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 58,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027959 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 74,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,404 Underlying: Ordinary Shares · 74,404 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 18,601 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 18,601 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027, and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 4 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,024 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025917 · ownership.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025917 · ownership.xml · derivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,701 Underlying: Ordinary Shares · 24,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 24,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025917 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023528 · ownership.xml · derivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023528 · ownership.xml · nonDerivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 12:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 58,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009610 · ownership.xml · derivative · entry 1 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,133 Underlying: Ordinary Shares · 58,133 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 23,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 7 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,529 Underlying: Ordinary Shares · 23,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022 and March 5, 2023, 23,764 vesting on March 5, 2024, and 23,765 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vested on each of March 5, 2022 and March 5, 2023, 23,764 vesting on March 5, 2024, and 23,765 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 23,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · nonDerivative · entry 3 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 6 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,536 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · derivative · entry 5 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,921 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016714 · doc4.xml · nonDerivative · entry 2 Sabag Mark · CIK 0001721442 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.